Blog

Admedus TAVR project on track with new IP applications

24, October, 2017

Posted In: Featured, In the media, Blog

Admedus Ltd today announced that it has submitted IP applications relating to the development of a new Transcatheter Aortic Valve Replacement (TAVR) device. Read the full ASX statement here.

> Read more

Notice of 2017 Annual General Meeting

13, October, 2017

Posted In: Blog

Admedus is pleased to announce the Annual General Meeting will be held at 11.00am (AEST) on 16 November 2017, at the Novotel Hotel in Brisbane, Australia.

> Read more

Investor webinar 5 September 2017

1, September, 2017

Posted In: Featured, In the media, Videos, Blog

Admedus Limited (ASX: AHZ) held an investor webinar on 5 September, 2017 to discuss the results of the Company’s Preliminary Final Report (Appendix 4E) for the year ended 30 June 2017.  Admedus CEO Wayne Paterson will provide a review of the Company’s year-end performance as well as operational and business highlights.

> Read more

Admedus announces exclusive supply agreement with 4C Medical

Admedus announces exclusive supply agreement with 4C Medical

31, August, 2017

Posted In: In the media, Blog

Admedus Limited is pleased to announce that it has entered an exclusive supply agreement with 4C Medical Technologies, Inc. (4C Medical), a Minnesota-based developer of minimally invasive therapies for structural heart disease. Read more here.

> Read more

Admedus attracts keen interest from surgeons at symposium

11, July, 2017

Posted In: Featured, Blog

Professor Leon Neethling recently attended the 53rd Annual Meeting of the Japanese Society of Paediatric Cardiology and Cardiac Surgery, in Hamamatsu, where he presented at a lunch symposium to more than 180 congenital surgeons from Japan, Vietnam, Philippines, Malaysia, Taiwan and Korea about our ADAPT products as part of the 13th Japan-China-Korea Paediatric Heart Forum.

> Read more

Admedus welcomes new Chief Operating Officer

9, June, 2017

Posted In: Blog

Admedus welcomes David St. Denis as our new Chief Operating Officer. Read the full Company announcement here.

> Read more

CardioCel: 8 years on and still free from calcification

23, August, 2016

Posted In: Blog, Uncategorized

CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]

> Read more

Using the ADAPT engineering process to create durable tissue scaffolds

8, July, 2016

Posted In: Blog, Uncategorized

Admedus is an Australian-based healthcare company leading the world in regenerative medicine and tissue engineering research. Using its proprietary ADAPT® tissue engineering technology, Admedus can transform xenograft (animal) tissue into durable bio-scaffolds that can be used for soft tissue repair within patients. The medical technology was first brought to Australia over 20 years ago by […]

> Read more

Admedus a major distributor of infusion solutions

10, June, 2016

Posted In: Blog, Uncategorized

Many people would have heard about the great work Admedus is doing in the field of tissue engineering and immunotherapies, but fewer people would know that Admedus is also a major distributor of infusion solutions (intravenous products and infusion pumps) to hospitals in Australia and New Zealand. The highly successful infusion portfolio has been part […]

> Read more

A day with Europe’s leading cardiovascular surgeons

5, May, 2016

Posted In: Blog, Uncategorized

In April, I had the privilege of spending the day with over forty of Europe’s leading cardiovascular surgeons. The purpose – an Admedus workshop to discuss the use of CardioCel to reconstruct heart valves and its potential in the future treatment of heart valve disease. Held in Amsterdam, the experts meeting shed light on the critical issues and […]

> Read more